When to intubate in GCS?

GCS ≤ 8 requires intubation for airway protection. The patient cannot protect their own airway at this level of consciousness. Motor score is the most prognostically important component.

What is the best initial fluid for sepsis resuscitation?

Lactated Ringer's (LR) is the preferred resuscitation fluid. The SMART trial (2018) showed balanced crystalloids reduced death, new renal failure, and persistent renal dysfunction compared to normal saline.

When to start vasopressors in septic shock?

Start norepinephrine (first-line vasopressor) if MAP remains < 65 mmHg after initial 30 mL/kg crystalloid resuscitation, or earlier if patient is profoundly hypotensive. Do not delay pressors to complete full fluid resuscitation.

Why can serum uric acid be normal during acute gout?

During acute inflammation, IL-6 increases renal urate excretion and redistributes urate from plasma to tissues. Up to 40% of acute gout flares have normal serum uric acid. Joint aspiration with polarized microscopy is needed for definitive diagnosis.

How do you distinguish lupus flare from infection in SLE?

Key clues: CRP is low/normal in flare but elevated in infection. Complement (C3/C4) drops in flare but is normal/elevated in infection. Procalcitonin is elevated in bacterial infection but normal in flare. Anti-dsDNA rises in flare, stable in infection.

What is the difference between DKA and HHS?

DKA features acidosis (pH 600), hyperosmolality (> 320), and minimal ketosis -typically in Type 2 DM. DKA requires insulin drip; HHS requires aggressive fluid resuscitation first.

When to give tPA in acute ischemic stroke?

IV alteplase (tPA) can be given within 4.5 hours of last known well time in eligible patients. CT head must rule out hemorrhage first. For large vessel occlusion, mechanical thrombectomy can be performed up to 24 hours with favorable imaging.

What antibiotics for community-acquired pneumonia?

Inpatient non-ICU: ceftriaxone + azithromycin. ICU: ceftriaxone + azithromycin (add vancomycin if MRSA risk). Outpatient healthy: amoxicillin. Outpatient with comorbidities: augmentin + azithromycin or respiratory fluoroquinolone. Duration: 5 days if clinically stable for 48 hours.

How to interpret iron studies?

Iron deficiency: low ferritin (< 30), high TIBC, low iron, low transferrin saturation (< 20%). Anemia of chronic disease: normal/high ferritin (acute phase reactant), low TIBC, low iron. A ferritin of 50-100 in an inflamed patient may still represent iron deficiency.

What is the correction rate for hyponatremia?

Correct sodium no more than 8 mEq/L in 24 hours to avoid osmotic demyelination syndrome (ODS). For symptomatic severe hyponatremia with seizures, give 3% hypertonic saline 100-150 mL bolus over 10-20 minutes. If overcorrected, use D5W + DDAVP rescue protocol.

When to start antibiotics in meningitis?

Within 30-60 minutes. Do NOT delay antibiotics for LP or CT. Draw blood cultures, start empiric antibiotics (vancomycin + ceftriaxone ± ampicillin if > 50 or immunocompromised), then perform LP when possible. Dexamethasone should be given before or with the first antibiotic dose.

DOACs vs warfarin in antiphospholipid syndrome?

DOACs are contraindicated in APS. The TRAPS trial (2018) showed rivaroxaban was inferior to warfarin with more thrombotic events in triple-positive APS patients. Warfarin with INR target 2-3 is the standard for APS, indefinitely.

How to manage scleroderma renal crisis?

ACE inhibitors (captopril) are life-saving -start immediately and titrate aggressively. Do NOT hold for rising creatinine. Steroids > 15 mg prednisone per day precipitate scleroderma renal crisis. ARBs are NOT a substitute -evidence is only for ACEi.

What are the 4 pillars of heart failure treatment?

Guideline-directed medical therapy (GDMT) for HFrEF: (1) ARNI or ACEi/ARB, (2) beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), (3) MRA (spironolactone or eplerenone), (4) SGLT2 inhibitor (dapagliflozin or empagliflozin). All four should be initiated and titrated to target doses.

Heart Failure -GDMT Four Pillars -RoundsRx

🔍 Overview

Classification

Type	EF	Pathology	Key Feature
HFrEF (systolic)	≤ 40%	Impaired contraction	*GDMT proven to reduce mortality.** All four pillars apply. *GDMT = Guideline-Directed Medical Therapy
HFmrEF (mid-range)	41–49%	Borderline -may behave like either	Emerging data supports GDMT (especially SGLT2i). Treat like HFrEF if symptomatic.
HFpEF (diastolic)	≥ 50%	Impaired relaxation / filling	No mortality-reducing GDMT until SGLT2i. Manage volume, comorbidities, and now SGLT2i.

NYHA Functional Classification

Class	Symptoms	Implication
I	No limitation. Ordinary activity does not cause symptoms.	Optimize GDMT. Continue current regimen.
II	Slight limitation. Comfortable at rest, symptoms with ordinary activity.	Ensure all four pillars are at target doses.
III	Marked limitation. Comfortable at rest, symptoms with less than ordinary activity.	Maximize GDMT. Consider ICD/CRT. Diuretic optimization.
IV	Unable to carry on any activity without symptoms. Symptoms at rest.	Advanced HF referral. Evaluate for LVAD / transplant.

Key Prognostic Markers

BNP / NT-proBNP -higher levels = worse prognosis. Useful for tracking response to therapy.
Hyponatremia (Na⁺ < 135) -independent predictor of mortality in HF
Peak VO₂ -gold standard for transplant candidacy (≤ 14 mL/kg/min → list)
NYHA class -class III/IV = ↑ mortality
EF -lower EF = higher mortality, but HFpEF also carries significant morbidity

Emerging Therapies

Digitoxin -DIGIT-HF, 2025 showed digitoxin 0.07 mg daily reduced death + HF hospitalization by 18% in advanced HFrEF (NYHA III–IV) on GDMT. Consider as add-on after optimizing all four pillars.

💊 GDMT -The Four Pillars (HFrEF)

▶ How to Escalate GDMT in HFrEF, Step by Step (tap to expand)

Paradigm shift (STRONG-HF, 2022): the old "titrate one drug to max, then add the next" model is dead. Current practice is start all four pillars at low dose within days, then uptitrate over 4-6 weeks. STRONG-HF (Lancet 2022) randomized 1,078 ADHF patients to rapid vs usual uptitration within 2 weeks of discharge: 34% reduction in 180-day death or HF hospitalization. Class I recommendation in the 2022 AHA/ACC/HFSA guideline.

Step 1: Confirm and stabilize before initiating

Check	What	Why
Confirm HFrEF	Echo with EF ≤ 40% (or HFmrEF 41-49%, treat same way per 2022 guideline)	4-pillar GDMT only proven to reduce mortality in HFrEF/HFmrEF. HFpEF gets different management (see HFrEF vs HFpEF section).
Stabilize hemodynamics	SBP ≥ 90, off pressors, no active cardiogenic shock	Starting ARNI or BB in shock will deepen the shock. Stabilize first, then layer GDMT. Loop diuretics for congestion don't wait.
Baseline labs	BMP (K+, Cr, eGFR), NT-proBNP or BNP, iron studies (ferritin, TSAT)	Hyperkalemia or AKI changes which pillars you can safely start. NT-proBNP trends gauge decongestion. Iron deficiency (ferritin < 100, or 100-299 with TSAT < 20%) needs IV iron (AFFIRM-AHF).

Step 2: Start all four pillars at low dose within days

Order in practice: the pillars don't need to be started on the same day, but all four should be on board within 2 weeks of discharge. A common sequencing (when staggered) is SGLT2i + low-dose BB on day 1 (most BP-neutral), then add ARNI day 2-3, then MRA day 3-7 once K+ stable. ARNI requires 36-hour washout from any ACEi (angioedema risk from dual neprilysin/ACE inhibition).

Pillar	Starting Dose	Why Low to Start
1. ARNI (sacubitril/valsartan)	49/51 mg BID if previously on ACEi/ARB and SBP ≥ 100; 24/26 mg BID if naive, elderly, or SBP 95-100	20% MACE reduction vs enalapril (PARADIGM-HF). Start low to limit hypotension and AKI; the BP drop is front-loaded.
1 (alt). ACEi/ARB if ARNI not affordable	Lisinopril 2.5-5 mg, enalapril 2.5 mg BID, losartan 25 mg, valsartan 40 mg BID	Mortality benefit in CONSENSUS/SOLVD. Use as a placeholder until ARNI is accessible. Don't combine ARNI with ACEi.
2. Beta-blocker	Carvedilol 3.125 mg BID, metoprolol succinate 12.5-25 mg daily, or bisoprolol 1.25 mg daily	Only these three BBs are evidence-based (MERIT-HF, COPERNICUS, CIBIS-II). Atenolol, propranolol, metoprolol tartrate are NOT acceptable substitutes. Negative inotropy at start makes congestion worse if patient is wet, so don't start during active decompensation.
3. MRA	Spironolactone 12.5-25 mg daily, or eplerenone 25 mg daily	30% mortality reduction (RALES, EMPHASIS-HF). Hold if K+ > 5.0 or eGFR < 30. Eplerenone if gynecomastia is a concern (less anti-androgen activity).
4. SGLT2i	Dapagliflozin 10 mg or empagliflozin 10 mg daily (no titration)	25-30% reduction in CV death + HF hospitalization (DAPA-HF, EMPEROR-Reduced), benefit regardless of diabetes status. Expect a 0.2 mg/dL Cr bump (hemodynamic, reverses; do not stop). Initiate down to eGFR 20.

Step 3: Uptitrate over 4-6 weeks to target doses

Drug	Target Dose	How to Titrate
Sacubitril/valsartan	97/103 mg BID	Double the dose q2-4 weeks if SBP and K+ tolerate. Recheck BMP at 1-2 weeks after each step.
Carvedilol	25 mg BID (50 mg BID if > 85 kg)	Double q2 weeks. Hold uptitration if HR < 55 or SBP < 90.
Metoprolol succinate	200 mg daily	Double q2 weeks (12.5 → 25 → 50 → 100 → 200).
Bisoprolol	10 mg daily	Double q2 weeks (1.25 → 2.5 → 5 → 10).
Spironolactone	25-50 mg daily	BMP at 3 days, 1 week, then monthly. Hold if K+ > 5.5.
Dapagliflozin / empagliflozin	10 mg daily (no titration)	One-dose drug. Counsel on euglycemic DKA, GU mycotic infection, sick-day rules.

Step 4: 3-month reassessment

Repeat echo at 3 months on optimized GDMT before any device decision. 30-40% of new HFrEF will recover EF > 35% on GDMT and won't need an ICD. Premature ICD in a recovered patient is a permanent device they didn't need.

EF recovers > 35%: continue GDMT lifelong (do NOT stop; TRED-HF showed 40% relapse rate within 6 months of withdrawal). No ICD.
EF stays ≤ 35%, NYHA II-III on optimized GDMT for ≥ 3 months: primary-prevention ICD (Class I).
EF ≤ 35% + LBBB ≥ 150 ms + NYHA II-IV: CRT-D (strongest indication; Class I).

Step 5: Add-on therapies if persistent symptoms despite optimized 4-pillar

Drug	When to Add	Why
Hydralazine + ISDN	Self-identified Black patients, NYHA III-IV on optimized GDMT	A-HeFT (2004): 43% mortality reduction in Black patients added to ACEi/BB. Class I in this population.
Ivabradine (Corlanor)	NSR with HR ≥ 70 despite max-tolerated BB, NYHA II-III, EF ≤ 35%	SHIFT (2010): 18% reduction in CV death/HF hospitalization. Funny-current (I_f) inhibitor in SA node; only works in NSR. Class IIa.
Vericiguat (Verquvo)	Recent worsening HF (hospitalization or IV diuretic) despite optimized GDMT	VICTORIA (2020): 10% reduction in CV death/HF hospitalization in high-risk worsening-HF patients. Soluble guanylate cyclase stimulator. Class IIb.
Digoxin	Persistent symptoms despite all above, or AF rate control overlay	DIG trial: no mortality benefit but reduces HF hospitalization. Narrow therapeutic window (target 0.5-0.9 ng/mL); higher levels increase mortality.
IV iron (ferric carboxymaltose)	Iron deficiency (ferritin < 100, or 100-299 with TSAT < 20%)	AFFIRM-AHF (2020): 26% reduction in HF hospitalization at 52 weeks. Treat even if Hb is normal -iron deficiency in HF is symptomatic without anemia.

Step 6: Advanced therapies (refractory NYHA IV)

Refer to advanced HF / transplant program early if any of: persistent NYHA IV symptoms, recurrent admissions, intolerance to GDMT, escalating diuretic doses, SBP < 90 limiting GDMT, INTERMACS profile 1-3, peak VO₂ < 14 mL/kg/min. Options: LVAD (bridge to transplant, bridge to candidacy, or destination therapy), heart transplant, palliative inotropes (dobutamine, milrinone) for symptom relief in end-stage.

Shortcuts that override the ladder

Scenario	Do This	Why
Cardiogenic shock (SBP < 90, on pressors)	Hold all 4 pillars; continue loop diuretic at adjusted dose. Resume sequentially once off pressors and Cr stable.	Each pillar drops BP, blunts SNS, or worsens hemodynamics in shock. Restart in order: ACEi/ARB/ARNI → BB → MRA → SGLT2i.
AKI with Cr rise > 30% from baseline	Hold ACEi/ARB/ARNI and MRA; continue SGLT2i and BB (SGLT2i Cr bump is hemodynamic and reverses)	RAAS-blockade and MRA cause true GFR drop that doesn't reverse if pushed; SGLT2i bump is intraglomerular pressure normalization (renoprotective long-term).
Hyperkalemia (K+ > 5.5)	Don't stop the MRA reflexively -try patiromer or sodium zirconium cyclosilicate (SZC) first. DIAMOND (2022) showed K+ binders allow MRA continuation.	MRA mortality benefit is lost if discontinued. Binders preserve GDMT. Class IIa in the 2022 guideline.
SBP < 90 limiting titration	Prioritize BB and SGLT2i (less BP-dependent for mortality benefit); use lower-dose ARNI or hold ARNI; reduce non-GDMT BP-lowering agents (CCBs, alpha-blockers).	BB and SGLT2i mortality benefit holds at lower BPs. Don't abandon mortality drugs to chase a BP number.
HR < 55 or symptomatic bradycardia	Hold further BB uptitration; reassess for AV block; consider ivabradine if NSR and HR remains ≥ 70 at max-tolerated BB later	BB still has mortality benefit at submaximal doses (don't abandon it). Bradycardia at low BB dose may unmask underlying conduction disease.
Active decompensation (admitted, congested, on IV diuretic)	Don't initiate BB; continue if already on it (B-CONVINCED). OK to initiate ARNI/ACEi/MRA/SGLT2i if hemodynamically stable.	Negative inotropy of BB in a wet patient worsens cardiac output and congestion. Once euvolemic and stable, start BB before discharge.
HFpEF (EF ≥ 50%)	SGLT2i first (EMPEROR-Preserved, DELIVER), then consider MRA (TOPCAT signal in Americas), diuretic for congestion. Treat HTN, AF, OSA, obesity aggressively.	HFpEF has no ARNI/BB mortality benefit. SGLT2i is the only class with clean HFpEF outcome data. Class I (SGLT2i) in 2023 focused update.
HFmrEF (EF 41-49%)	Treat as HFrEF -all 4 pillars (Class IIa in 2022 guideline)	Pooled data and DELIVER subgroup show similar benefit to HFrEF. Don't undertreat just because EF is borderline.

The Four Pillars of HFrEF

All four pillars should be initiated and uptitrated in every HFrEF patient (EF ≤ 40%) unless contraindicated. Each independently reduces mortality. Together, they reduce HF mortality by ~70% compared to no treatment. Get them all on board -don't wait to finish one before starting the next.

Pillar	Drug (Brand)	Target Dose	Key Trial	Mortality Reduction	Watch Out
1. ARNI* *= Angiotensin Receptor-Neprilysin Inhibitor (sacubitril-valsartan) 1ST LINE	Sacubitril/valsartan (Entresto) Start 24/26 mg BID → target 97/103 mg BID	97/103 mg BID	PARADIGM-HF, 2014	20% reduction in composite CV death + HF hospitalization vs enalapril (16% RRR for all-cause mortality)	Hold ACEi 36h before starting (angioedema risk). Hypotension. Do not use with ACEi. Avoid if SBP < 100.
1. ACEi/ARB (if ARNI not tolerated)	Enalapril (Vasotec) 10–20 mg BID Lisinopril (Zestril) 20–40 mg daily Losartan (Cozaar) 50–150 mg daily Valsartan (Diovan) 160 mg BID	Max tolerated	CONSENSUS, 1987 SOLVD, 1991	~25–30%	Hyperkalemia, AKI, cough (ACEi). Monitor Cr + K⁺ at 1–2 weeks. Cr rise ≤ 30% acceptable.
2. Beta-blocker 1ST LINE	Carvedilol (Coreg) 3.125 → 25 mg BID Metoprolol succinate (Toprol-XL) 12.5 → 200 mg daily Bisoprolol 1.25 → 10 mg daily	Max tolerated of one of the three	MERIT-HF, 1999 COPERNICUS, 2001 CIBIS-II, 1999	~35%	Only these three BBs are evidence-based for HFrEF. Atenolol, propranolol, etc. have no HF data. Start low, go slow. Do NOT start during decompensation.
3. MRA* *= Mineralocorticoid Receptor Antagonist (spironolactone, eplerenone) 1ST LINE	Spironolactone (Aldactone) 12.5–50 mg daily or Eplerenone (Inspra) 25–50 mg daily	25–50 mg daily	RALES, 1999 EMPHASIS-HF, 2011	~30%	Hyperkalemia -monitor K⁺ at 3 days, 1 week, monthly. Avoid if K⁺ > 5.0 or eGFR < 30. Eplerenone = less gynecomastia than spironolactone.
4. SGLT2 inhibitor 1ST LINE	Dapagliflozin (Farxiga) 10 mg daily or Empagliflozin (Jardiance) 10 mg daily	10 mg daily (no titration needed)	DAPA-HF, 2019 EMPEROR-Reduced, 2020	~25% reduction in CV death + HF hospitalization. Benefit independent of diabetes status.	Expect a ~0.2 Cr bump when starting (hemodynamic, not injury, reverses). Avoid if eGFR < 20 or T1DM (euglycemic DKA risk). Watch for GU mycotic infections. Hold peri-operatively or if NPO for > 24h.

🫀 HFrEF vs HFpEF

HFrEF vs HFpEF -Management Comparison

Classification: HFrEF = EF ≤ 40% | HFmrEF = EF 41–49% | HFpEF = EF ≥ 50%. Management differs fundamentally -HFrEF has strong mortality-reducing GDMT; HFpEF treatment is largely symptom-driven with emerging evidence for SGLT2 inhibitors.

Domain	HFrEF (EF ≤ 40%)	HFpEF (EF ≥ 50%)
Core pathology	Systolic dysfunction -weakened pump. Dilated LV, ↓ contractility.	Diastolic dysfunction -stiff ventricle. Normal LV size, impaired relaxation and filling.
ARNI / ACEi / ARB	MORTALITY BENEFIT ARNI preferred over ACEi/ARB. PARADIGM-HF, 2014: sacubitril/valsartan reduced CV death + HF hospitalization by 20% vs enalapril.	NO PROVEN BENEFIT PARAGON-HF, 2019: ARNI did not significantly reduce primary endpoint vs valsartan. Possible benefit in lower EF range (EF ≤ 57%).
Beta-blocker	MORTALITY BENEFIT Carvedilol, metoprolol succinate, or bisoprolol. COPERNICUS, 2001: carvedilol reduced mortality 35% in severe HFrEF. MERIT-HF, 1999: metoprolol succinate reduced mortality 34%.	NO PROVEN BENEFIT No mortality benefit in HFpEF trials. Use for rate control (Afib) or HTN -not as HF-specific therapy.
MRA	MORTALITY BENEFIT RALES, 1999: spironolactone reduced mortality 30% in severe HFrEF. EPHESUS, 2003: eplerenone in post-MI HFrEF.	POSSIBLE BENEFIT TOPCAT, 2014: overall negative, but Americas subgroup showed benefit. Consider if symptomatic despite diuretics.
SGLT2 inhibitor	MORTALITY BENEFIT DAPA-HF, 2019: dapagliflozin reduced worsening HF/CV death 26%. EMPEROR-Reduced, 2020: empagliflozin confirmed class effect.	HF HOSPITALIZATION BENEFIT EMPEROR-Preserved, 2021: empagliflozin reduced CV death + HF hospitalization 21%. DELIVER, 2022: dapagliflozin confirmed across EF spectrum. Only drug class with clear benefit in HFpEF.
Diuretics	Symptom relief. Loop diuretics for congestion. No mortality benefit but essential for decongestion.	Cornerstone of symptom management. Low-dose loop diuretics. Avoid over-diuresis -these patients are preload-dependent.
GLP-1 RA	No specific HFrEF indication. Use for comorbid T2DM/obesity.	EMERGING STEP-HFpEF, 2023: semaglutide improved symptoms, exercise capacity, and weight in obese HFpEF. Targets the obesity-HFpEF phenotype.
Comorbidity focus	ICD/CRT if EF ≤ 35% on optimal GDMT × 3 months. Cardiac rehab. Iron repletion if deficient.	Central to management. Aggressive HTN control, Afib rate control (restore atrial kick), weight loss, OSA treatment, glycemic control, exercise training. Ex-DHF, 2011: exercise training improved peak VO₂ and quality of life.
Devices	ICD if EF ≤ 35% + NYHA II–III on optimal GDMT ≥ 3 months (SCD-HeFT, 2005). CRT if EF ≤ 35% + LBBB + QRS ≥ 150ms.	No role for ICD or CRT. EF is preserved -sudden death risk is lower.

Key takeaway: HFrEF has 4 mortality-reducing drug classes (ARNI, BB, MRA, SGLT2i) -start all four early and titrate to targets. HFpEF management centers on SGLT2 inhibitors (the only drug class with clear evidence), aggressive diuresis for symptoms, and treating every comorbidity (HTN, obesity, Afib, DM, OSA). The days of "nothing works for HFpEF" are over -SGLT2i changed the game.

🔧 Device Therapy

ICD (Implantable Cardioverter-Defibrillator)

Primary prevention ICD indications in HFrEF:

EF ≤ 35% despite ≥ 3 months of optimal GDMT
NYHA class II–III
Expected survival > 1 year
Wait ≥ 40 days post-MI and ≥ 90 days post-revascularization before implant MADIT-II, 2002 SCD-HeFT, 2005

Secondary prevention: Any survivor of VT/VF arrest or sustained VT with hemodynamic compromise → ICD regardless of EF.

CRT (Cardiac Resynchronization Therapy)

EF ≤ 35% + LBBB with QRS ≥ 150 ms + NYHA II–IV on optimal GDMT → strongest indication (class I)
LBBB with QRS 120–149 ms → class IIa
Non-LBBB with QRS ≥ 150 ms → class IIa (weaker benefit)
QRS < 120 ms → NO benefit from CRT

MADIT-CRT, 2009: CRT-D reduced HF events by 34% in LBBB patients. RAFT, 2010: CRT-D reduced mortality by 25% vs ICD alone in LBBB.

Advanced HF -When to Refer

NYHA III–IV despite maximal GDMT
≥ 2 HF hospitalizations in 12 months
Rising BNP/NT-proBNP despite optimization
Refractory volume overload requiring frequent IV diuretics
Declining renal function (cardiorenal syndrome)
Consideration for LVAD (bridge to transplant or destination therapy) or heart transplant

📋 On Rounds

Pimp Questions

What are the four pillars of HFrEF GDMT?

(1) ARNI (sacubitril/valsartan) or ACEi/ARB, (2) evidence-based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol -only these three), (3) MRA (spironolactone or eplerenone), (4) SGLT2 inhibitor (dapagliflozin or empagliflozin). All four independently reduce mortality. Together, ~70% mortality reduction.

Why is sacubitril/valsartan (Entresto) better than enalapril?

PARADIGM-HF, 2014: sacubitril/valsartan reduced CV death by 20% and HF hospitalization by 21% compared to enalapril. Sacubitril is a neprilysin inhibitor -it prevents breakdown of natriuretic peptides (BNP, ANP) → enhanced natriuresis, vasodilation, and neurohormonal modulation. Must hold ACEi × 36h before switching (angioedema risk from dual enzyme inhibition).

Which beta-blockers are evidence-based in HFrEF?

Only three: carvedilol COPERNICUS, 2001, metoprolol succinate MERIT-HF, 1999, and bisoprolol CIBIS-II, 1999. Atenolol, propranolol, metoprolol tartrate, and other beta-blockers have NO evidence for mortality reduction in HFrEF. Metoprolol tartrate ≠ metoprolol succinate -the succinate (extended release) formulation is the one with the trial data.

What was the first drug to show benefit in HFpEF?

SGLT2 inhibitors. EMPEROR-Preserved, 2021: empagliflozin reduced HF hospitalization by 21% in HFpEF. DELIVER, 2022: dapagliflozin reduced HF composite by 18%. Before this, decades of trials failed in HFpEF -ACEi, ARBs, digoxin, and spironolactone all showed no or equivocal mortality benefit. SGLT2i are now first-line for all HF regardless of EF.

When do you refer for ICD vs CRT?

ICD: EF ≤ 35% despite ≥ 3 months GDMT, NYHA II–III, expected survival > 1 year. Wait ≥ 40 days post-MI. CRT: same EF criteria PLUS LBBB with QRS ≥ 150 ms (strongest indication). Non-LBBB or QRS 120–149 have weaker evidence. QRS < 120 ms = no CRT benefit. Most patients who qualify for CRT also get a combined CRT-D (CRT + defibrillator).

Clinical Examples

📋 Case 1, New HFrEF Diagnosis: Initiating GDMT

Patient: 55M with HTN and T2DM, presents with 3 weeks of progressive dyspnea on exertion, orthopnea (3-pillow), and bilateral leg swelling. No prior cardiac history.

Key findings: BP 142/88, HR 92, SpO2 95% on RA, JVD, bilateral crackles to mid-lung, 2+ pitting edema. BNP 1,840. Echo: EF 25%, global hypokinesis, no significant valvular disease. Troponin negative x2.

Management:

IV furosemide 40 mg q12h for decongestion, daily weights, strict I/Os, Na < 2g/day
Start all 4 pillars of GDMT simultaneously: sacubitril/valsartan 24/26 mg BID, carvedilol 3.125 mg BID, spironolactone 25 mg daily, empagliflozin 10 mg daily DAPA-HF, 2019
Check BMP in 1 week (K+ and Cr on ARNI + MRA). Hold MRA if K+ > 5.0 or eGFR < 30
Uptitrate ARNI and BB at 2-week intervals to target doses as tolerated

Teaching point: Current guidelines favor starting all 4 GDMT pillars early rather than sequential addition. SGLT2i can be started regardless of diabetes status. The STRONG-HF, 2022 trial showed rapid uptitration is safe and improves outcomes.

📋 Case 2, Acute Decompensated HF with Cardiogenic Shock

Patient: 68F with known HFrEF (EF 20%), on sacubitril/valsartan, carvedilol, spironolactone, and dapagliflozin. Presents with worsening dyspnea at rest x 2 days, unable to lie flat.

Key findings: BP 82/54, HR 110, SpO2 88% on 4L NC, cool extremities, mottled skin. Lactate 4.2. BNP 5,600. CXR: pulmonary edema. PA catheter: CI 1.6, PCWP 32, SVR 2,100 ("cold and wet" profile).

Management:

Hold BB, ARNI, MRA in acute cardiogenic shock (restart once hemodynamically stable)
IV milrinone (preferred if on chronic BB -- does not compete with beta receptors) or dobutamine for inotropy
IV furosemide drip (double home dose) for decongestion once perfusion improves
If refractory: consider mechanical circulatory support (Impella, IABP). Cardiology and CT surgery consult

Teaching point: In cardiogenic shock, hold all GDMT that lowers BP or HR. The "cold and wet" profile requires inotropes before diuresis. Use the Stevenson classification (warm/cold, wet/dry) to guide management.

📋 Case 3, HFpEF with Recurrent Admissions

Patient: 74F with obesity (BMI 38), HTN, T2DM, and Afib, presents with third HF admission in 6 months. Dyspnea on minimal exertion, 8 lb weight gain over 2 weeks despite taking furosemide 40 mg daily at home.

Key findings: BP 158/92, HR 84 (irregular), SpO2 93% on RA, elevated JVP, bibasilar crackles, 3+ edema. BNP 680. Echo: EF 62%, grade II diastolic dysfunction, moderate TR, RVSP 52. H2FPEF score: 8 (high probability of HFpEF).

Management:

IV diuresis: furosemide 80 mg IV BID (double oral dose for IV). Target net negative 1-2 L/day
Start empagliflozin 10 mg daily -- first drug class with proven benefit in HFpEF EMPEROR-Preserved, 2021
Aggressive BP control (target < 130/80), rate control for Afib (target HR < 110), weight loss counseling
Consider spironolactone 25 mg daily (reduces HF hospitalizations in HFpEF per TOPCAT, 2014 Americas subgroup)

Teaching point: SGLT2 inhibitors are the first drug class to show clear benefit across the entire EF spectrum. In HFpEF, focus on treating comorbidities (HTN, obesity, Afib, volume status) since no other drug has proven mortality benefit.

📣 Sample Presentation

One-Liner

"Mr. Lopez is a 62-year-old with HFrEF (EF 30%), NYHA class II, currently on lisinopril 10 mg, carvedilol 12.5 BID, and furosemide 40 daily. Not on MRA or SGLT2i. Here for medication optimization."

Key Points to Cover on Rounds

EF 30%, NYHA II, currently on 2 of 4 GDMT pillars. Action plan: (1) Switch lisinopril → sacubitril-valsartan 24/26 BID (must wash out ACEi ×36h first), (2) Uptitrate carvedilol to 25 mg BID in 2 weeks, (3) Add spironolactone 25 mg daily (K⁺ 4.2, Cr 1.1 -safe), (4) Add dapagliflozin 10 mg daily. ICD candidacy: EF ≤ 35% on max GDMT ×3 months → reassess. CRT if LBBB + QRS ≥ 150. Cardiac rehab referral.

Monitoring Parameters -Chronic Heart Failure

Parameter	Frequency	Target / Action
Daily weights	Every morning, same scale, before breakfast	Weight gain > 2 lbs in 2 days or > 5 lbs in 1 week → call clinic / increase diuretic per action plan. Most important home monitoring tool.
BMP (K⁺, Cr, Na⁺)	1–2 weeks after each GDMT initiation or dose change; then q3–6 months when stable	K⁺ 4.0–5.0 (RAAS inhibitors + MRA raise K⁺, diuretics lower it). Cr rise ≤ 30% acceptable on ACEi/ARB/ARNI. Na < 130 → fluid restrict.
Blood pressure	Each clinic visit; home monitoring encouraged	SBP ≥ 90 for ARNI/ACEi/ARB titration. Tolerate asymptomatic low SBP (90–100) if on optimal GDMT. Symptomatic hypotension → reduce diuretic first, then GDMT.
Heart rate	Each clinic visit	Resting HR 60–70 on maximally tolerated beta-blocker. HR ≥ 70 despite max BB → consider ivabradine (if sinus rhythm, EF ≤ 35%).
BNP / NT-proBNP	Baseline, then to track response to therapy	> 30% reduction from baseline = good prognostic sign. Do not chase a specific number -trend matters more than absolute value. If on sacubitril/valsartan (Entresto), trend NT-proBNP, not BNP -neprilysin inhibition falsely elevates BNP, while NT-proBNP is unaffected. Why ↗
Echocardiogram (EF)	Repeat at 3–6 months after GDMT optimization	EF improvement → continue all GDMT (may reclassify HFrEF → HFimpEF). LBBB + EF ≤ 35% + QRS > 150 ms → CRT candidate.
Functional status (NYHA class)	Each visit	Dyspnea, exercise tolerance, orthopnea, PND. NYHA III–IV despite optimal GDMT → advanced HF referral (LVAD/transplant evaluation).
Iron studies	At diagnosis, then annually	Ferritin < 100 or ferritin 100–300 + TSAT < 20% → IV iron replacement. Improves functional capacity and reduces HF hospitalizations.

GDMT uptitration is the priority. At every visit, ask: "Can I increase any of the four pillars?" Uptitrate one drug at a time, every 1-2 weeks, to target dose or maximally tolerated dose. Do NOT wait for one pillar to be at target before starting the next - initiate all four early and uptitrate in parallel STRONG-HF, 2022.

🧪 Workup

Workup -Chronic Heart Failure

Echocardiogram -the single most important test. Establishes EF (HFrEF vs HFpEF vs HFmrEF), wall motion abnormalities, valvular disease, diastolic dysfunction, chamber sizes. Repeat at 3–6 months after GDMT optimization to reassess EF.
BNP / NT-proBNP -elevated in HF (BNP > 100, NT-proBNP > 300). Useful for diagnosis, prognosis, and monitoring response to therapy. Trend over time -> 30% reduction with treatment is a good prognostic sign. On an ARNI (sacubitril/valsartan, Entresto), monitor with NT-proBNP -BNP is falsely raised by neprilysin inhibition, NT-proBNP is not a neprilysin substrate.
BMP -baseline Cr, K⁺, Na⁺ before starting RAAS inhibitors and diuretics. Monitor after each dose change. Cr rise ≤ 30% acceptable on ACEi/ARB/ARNI. K⁺ must be < 5.0 for MRA initiation.
CBC -anemia worsens HF symptoms and is common (anemia of chronic disease, hemodilution). Iron studies if anemic -IV iron if ferritin < 100 or ferritin 100–300 + TSAT < 20% AFFIRM-AHF, 2020
TSH -hypo- and hyperthyroidism are reversible causes of HF. Check in all new diagnoses.
Iron studies -ferritin and TSAT. Iron deficiency is common in HF and independently worsens exercise capacity and outcomes, even without anemia.
ECG -LVH, prior MI, arrhythmia (AF common), conduction disease (LBBB -CRT candidate if QRS > 150 ms + EF ≤ 35%).
Cardiac MRI -if echo is inadequate, or to characterize etiology (ischemic vs non-ischemic, infiltrative, myocarditis, hemochromatosis, amyloid).

💊 Medications

Medications -Chronic Heart Failure (HFrEF)

All four pillars should be initiated in every HFrEF patient (EF ≤ 40%). See the GDMT (Four Pillars) tab above for detailed dosing, trials, and titration guidance.

Pillar	Drug (Brand)	Starting → Target Dose	Key Monitoring
1. ARNI	Sacubitril/valsartan (Entresto)	24/26 mg BID → 97/103 mg BID	BP, Cr, K⁺ at 1–2 weeks. Hold ACEi 36h before starting. SBP ≥ 90.
2. Beta-blocker	Carvedilol (Coreg) or metoprolol succinate (Toprol-XL)	Carvedilol 3.125 mg BID → 25 mg BID Metoprolol XL 12.5 mg → 200 mg daily	HR ≥ 60, SBP ≥ 90. Do NOT start during decompensation. Only these 3 BBs have evidence.
3. MRA	Spironolactone (Aldactone) or eplerenone (Inspra)	Spironolactone 12.5 → 25–50 mg daily Eplerenone 25 → 50 mg daily	K⁺ < 5.0 and Cr < 2.5 before starting. Recheck at 1 week. Eplerenone if gynecomastia from spironolactone.
4. SGLT2i	Dapagliflozin (Farxiga) or empagliflozin (Jardiance)	Dapagliflozin 10 mg daily Empagliflozin 10 mg daily	No titration needed. Works in diabetic AND non-diabetic HF. Watch for GU infections, euglycemic DKA (rare).

Additional Agents

Diuretics -furosemide (Lasix) for volume management. Symptom relief only -no mortality benefit. Titrate to dry weight.
Hydralazine/isosorbide dinitrate (BiDil) -add to GDMT in Black patients with NYHA III–IV (A-HeFT, 2004). Also for patients who cannot tolerate ACEi/ARB/ARNI.
Ivabradine (Corlanor) -if HR ≥ 70 on maximally tolerated beta-blocker, sinus rhythm, EF ≤ 35% SHIFT, 2010.
IV iron -ferric carboxymaltose (Injectafer) if ferritin < 100 or ferritin 100–300 + TSAT < 20%. Improves symptoms and reduces HF hospitalizations.

DIGIT-HF (NEJM 2025): Digitoxin 0.07 mg daily added to GDMT reduced the composite of death + HF hospitalization by 18% (HR 0.82, p=0.03) in advanced HFrEF (LVEF ≤40%, NYHA III-IV). Benefits consistent even on ARNI + SGLT2i. Consider after optimizing all four pillars. DIGIT-HF, 2025 Note: the older DIG, 1997 trial showed digoxin reduced HF hospitalizations 28% but had no mortality benefit.

⚡ Management

Management -Chronic Heart Failure

See the GDMT (Four Pillars) tab for the full treatment algorithm with drug dosing, target doses, and landmark trial citations. See the HFrEF vs HFpEF tab for a side-by-side management comparison. For acute decompensation management, see ADHF.

Iron Deficiency in HF -Different Cutoffs Than General Population

Iron deficiency affects up to 50% of HF patients (with or without anemia) and is independently associated with worse exercise capacity, quality of life, and HF hospitalization. The diagnostic thresholds in HF are different from the general population -ferritin is an acute-phase reactant, and chronic systemic inflammation in HF inflates it, masking true iron deficiency.

Population	Iron deficiency definition	Why this threshold
General adult	Ferritin < 30 ng/mL OR TSAT < 20% with ferritin < 100	Standard ID threshold; no inflammation correction needed.
Heart failure HIGHER FERRITIN CUTOFF	Absolute: ferritin < 100 ng/mL Functional: ferritin 100-299 ng/mL WITH TSAT < 20%	Chronic inflammation in HF elevates ferritin (acute-phase reactant). A "normal" ferritin (e.g., 80 ng/mL) in HF can mask iron-depleted stores. TSAT < 20% is more reliable -less affected by inflammation.

Practical lab combo to check in HF: ferritin + TSAT + serum iron + TIBC. Iron-saturation ratio (TSAT) catches the functional iron deficiency that ferritin alone misses. Don't be reassured by ferritin 50-150 in a HF patient with persistent fatigue and exercise intolerance -check TSAT.

What is TSAT (Transferrin Saturation), and why does it matter so much in HF? The percentage of transferrin (the iron-carrying transport protein) that is currently bound to iron. Formula: TSAT = (serum iron ÷ TIBC) × 100. Normal range: 20-50%. Iron deficiency: < 20%.

Why TSAT > ferritin in HF specifically: ferritin is a storage marker AND an acute-phase reactant -it rises with inflammation. HF is a state of chronic systemic inflammation, so a "normal-looking" ferritin (e.g., 80-150 ng/mL) can mask depleted iron stores. TSAT reflects circulating iron available for cardiomyocyte and skeletal-muscle mitochondria right now, and is much less inflated by inflammation. That's why the HF iron-deficiency definition explicitly includes TSAT < 20% as a functional criterion -it catches the patient who looks fine on ferritin alone but is functionally iron-starved.

Pre-test pearls: hold oral iron for 24-48 h before draw (recent dose falsely elevates TSAT). TSAT has diurnal variation (higher in AM) -fasting AM draw is most reliable for borderline cases.

Who to give iron to

HFrEF (EF ≤ 40%) AND iron-deficient (per HF criteria above) AND symptomatic (NYHA II-IV) -Class 2a per ACC/AHA 2022 and ESC 2023.
HFmrEF (EF 41-49%) -reasonable based on extrapolation; trial data sparser.
HFpEF (EF ≥ 50%) -individualize. Trials predominantly enrolled HFrEF; HFpEF iron data still emerging.
Acute HF admission with iron deficiency -AFFIRM-AHF, 2020 supports IV iron BEFORE discharge to reduce HF rehospitalization.

What to give -IV iron, not oral

Oral iron is generally ineffective in HF. Chronic inflammation drives high hepcidin → blocks intestinal iron absorption AND blocks iron release from stores. IRONOUT-HF, 2017 showed oral iron polysaccharide did NOT improve exercise capacity. Use IV iron.

Drug	Dose	Notes
Ferric carboxymaltose (Injectafer) PREFERRED	Up to 1000 mg IV per dose, max 1500 mg per cycle. Repeat in 3-6 mo if depleted.	Most-studied IV iron in HF (FAIR-HF, CONFIRM-HF, AFFIRM-AHF, HEART-FID). Watch transient hypophosphatemia (especially with repeat dosing).
Ferric derisomaltose (Monoferric) SINGLE-INFUSION	Up to 1500 mg IV in one dose (over 20-30 min)	IRONMAN, 2022 showed clinical-event reduction. Convenient single infusion. Less hypophosphatemia than ferric carboxymaltose.
Iron sucrose (Venofer) OLDER	200 mg IV per dose, multiple infusions needed	Older agent, requires more infusions (5-10 visits to repleting). Less convenient. Use only if newer agents unavailable.

Why give iron in HF -what does it actually do?

Improves exercise capacity (6-minute walk distance, peak VO₂) -CONFIRM-HF, 2015
Improves quality of life and NYHA class -FAIR-HF, 2009
Reduces HF hospitalization -AFFIRM-AHF (acute HF discharge), IRONMAN (chronic HF)
Mortality benefit -not robustly demonstrated; trials underpowered for individual mortality endpoint
Mechanism: iron is essential for mitochondrial function in cardiomyocytes and skeletal muscle. Repletion improves cellular energetics independent of correcting anemia.

Bottom line for rounds: In any HFrEF patient with NYHA II-IV symptoms, check ferritin + TSAT. Use the HF-specific cutoffs (ferritin < 100 absolute, OR ferritin 100-299 + TSAT < 20% functional). If iron-deficient, give IV ferric carboxymaltose 1000 mg (or ferric derisomaltose 1500 mg single dose). Don't bother with oral iron. Recheck labs in 3-6 months.

⚡ Summary

Summary

4 Pillars GDMT

ARNI (or ACEi) + evidence-based BB + MRA + SGLT2i. Start all four early. Each independently reduces mortality.

Key Trials

ARNI [PARADIGM-HF]. SGLT2i [DAPA-HF, EMPEROR-Reduced]. MRA [RALES]. BB [COPERNICUS, MERIT-HF].

Diuresis Goal

Net −1 to 2 L/day. Daily weights. UOP 100-150 mL/hr after IV furosemide. Metolazone for resistance.

ICD Criteria

EF ≤ 35% on max GDMT × 3 months, NYHA II-III, life expectancy > 1 year. CRT if LBBB + QRS ≥ 150.

HFpEF

EF ≥ 50%. Diuresis for congestion. SGLT2i (empagliflozin) [EMPEROR-Preserved]. Treat comorbidities: HTN, AF, obesity.

Discharge

Optimize GDMT before discharge. Weight target. Fluid restrict 1.5-2L/day. Follow-up within 7 days. Cardiac rehab.

📄 One Pager

One Pager -Heart Failure -Chronic Management

Print this page (Ctrl/Cmd + P) for a complete reference card. All tab content prints together.

HEART FAILURE -CHRONIC MANAGEMENT -AT A GLANCE

📋 Diagnose: See Overview
🧪 Workup: See Workup tab
⚡ Treat: See Management tab
💊 Drugs: See Medications tab
📣 Present: See Rounds tab

📄 One Pager

Cardiology · One Pager

CHF -Acute & Chronic

4 pillars of GDMT: ARNI + BB + MRA + SGLT2i. Start all four early. Diuresis for congestion. ICD if EF ≤ 35% on max GDMT × 3 months.

🧪 Classification

Warm/Wet (most common ADHF): diuretics. Cold/Wet: inotropes + diuretics. Cold/Dry: careful fluids. Warm/Dry: optimize GDMT outpatient.

🚨 Acute Management

IV furosemide 1-2.5× home dose. Target net −1 to 2L/day. Metolazone for resistance. Avoid inotropes unless cardiogenic shock. Continue GDMT unless hypotensive.

💊 4 GDMT Pillars

(1) ARNI [PARADIGM-HF] or ACEi. (2) BB: carvedilol, metoprolol succinate, or bisoprolol. (3) MRA: spironolactone [RALES]. (4) SGLT2i: dapagliflozin [DAPA-HF] or empagliflozin.

💊 Key Drugs

Furosemide IV40-200 mg bolus

Sacubitril-valsartan24/26 → 97/103 BID

Carvedilol3.125 → 25 mg BID

Spironolactone12.5-50 mg daily

Dapagliflozin10 mg daily

⚠️ Pitfalls

Holding BB in acute HF (continue unless cardiogenic shock)
Not starting all 4 GDMT pillars
Chasing BNP number instead of clinical volume status
Discharging without GDMT optimization + 7-day f/u